Clinical Studies

Stroke:

TARGET Intracranial Aneurysm Coiling Registry: A Prospective Clinical Efficacy and Safety Study of Stryker Target® 360° and Target® Helical Coils

A randomized, concurrent controlled trial to assess the safety and effectiveness of the Separator 3D as a component of the Penumbra System in the revascularization of large vessel occlusion in acute ischemic stroke (CGA #129004)-1 subject enrolled, currently enrolling

A pilot study of Aldosterone, Cortisol and Norepinephrine Levels in Patients with Acute, Large Vessel Ischemic Stroke—Investigator initiated

The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke

The Intravascular Cooling in the Treatment of Stroke 2/3 (ICTuS 2/3) Trial

Genetic Risk and AF Detection in Stroke (GRADS study)

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Evaluating Aspirin Inhibition of Platelet Aggregation in Patients Presenting with Ischemic Stroke and Diabetes –Investigator initiated

Seizure:

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study To Evaluate The Efficacy And Safety Of Brivarecetam In Subjects (>/= 16 TO 80 Years Old) With Partial Onset Seizures

Concussion:

A Pilot Study of Functional MRI, Diffusion Tensor Imaging and Traditional Neuro-Psychological Testing Biomarkers as Prognostic Tools in Sports Concussion

A Longitudinal Study of functional MRI, Diffusion Tensor Imaging and Traditional Neuro-Psychological Testing Biomarkers in Freshman Athletes following Sport-Related Concussion

MS:

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: Stratify-2

A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

The measurement of red blood cell ATP as a biomarker of multiple sclerosis disease activity

Pediatrics (Being performed by active MSU Faculty with off campus assignment in Sub-Saharan Africa.)

The burden of pediatric neurologic disease in Ethiopia

Epilepsy or Developmental Disability from Uncomplicated Malaria

Viral co-infections in retinopathy negative cerebral malaria

A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria

Parkinson’s Disease:

A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects with Treated Parkinson's Disease (PD)LS-1

A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson’s Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients with Parkinson’s Disease and Chronic Constipation Dissatisfied with Current Therapy

A randomized, double-blind, placebo-controlled trial of urate elevating inosine treatment to slow clinical decline in early Parkinson disease

Effects of task complexity on acoustic characteristics of Parkinsonian speech

Neural processes that influence the contents of working memory

Alzheimer’s Disease:

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

A Randomized, 18-week, Placebo-Controlled, Double-Blind,Parallel Group Study of the Safety and Efficacy of PF-05212377(SAM-760) in Subjects with Mild-to-Moderate Alzheimer’s Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

Additional research:

Distal Symmetric Polyneuropathies in Zambia

Conversion rate from ocular to generalized myasthenia gravis after 3 years of follow-up

Appearance of cavernous angiomas after brain radiation therapy

Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

MSU is an affirmative action, equal opportunity employer

© Michigan State University Board of Trustees, East Lansing, MI 48824